Ex vivo enrichment of PRAME antigen‐specific T cells for adoptive immunotherapy using CD137 activation marker selection

OBJECTIVE: Adoptive immunotherapy with ex vivo expanded tumor‐specific T cells has potential as anticancer therapy. Preferentially expressed antigen in melanoma (PRAME) is an attractive target overexpressed in several cancers including melanoma and acute myeloid leukaemia (AML), with low expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Koon H, Gowrishankar, Kavitha, Street, Janine, McGuire, Helen M, Luciani, Fabio, Hughes, Brendan, Singh, Mandeep, Clancy, Leighton E, Gottlieb, David J, Micklethwaite, Kenneth P, Blyth, Emily
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577233/
https://www.ncbi.nlm.nih.gov/pubmed/33101678
http://dx.doi.org/10.1002/cti2.1200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577233/
https://www.ncbi.nlm.nih.gov/pubmed/33101678
http://dx.doi.org/10.1002/cti2.1200

Ejemplares similares